The FDA requested new and updated information and clarifications related to drug substance, drug product, manufacturing, and microbiology. The FDA did not express concern about the stability of the ...
Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...
Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com. 3 Colijn JM, Liefers B ...
Nanotechnology, a groundbreaking field that involves manipulating matter at the molecular and atomic levels, is rapidly ...
A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...
The FDA has made some modest efforts, but it needs an internal organization that understands and would be an aggressive ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Eton Pharmaceuticals, Inc. announced that the FDA has extended the PDUFA goal date for its New Drug Application (NDA) for ET-400 to May 28, 2025, allowing the agency additional time to review ...
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results